ATAC-Seq in LNCaP cell line with GSK treatment and VEH control

ABSTRACT: We show in prostate cancer cells that LSD1 co-localizes with FOXA1 and active enhancer markers, and that LSD1 inhibition globally disrupts FOXA1 chromatin binding.

ORGANISM(S): Homo sapiens

PROVIDER: GSE148925 | GEO | 2020/07/14

REPOSITORIES: GEO